Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 83

1.

Corticobasal syndrome and primary progressive aphasia as manifestations of LRRK2 gene mutations.

Chen-Plotkin AS, Yuan W, Anderson C, McCarty Wood E, Hurtig HI, Clark CM, Miller BL, Lee VM, Trojanowski JQ, Grossman M, Van Deerlin VM.

Neurology. 2008 Feb 12;70(7):521-7.

2.

Corticobasal syndrome and primary progressive aphasia as manifestations of lrrk2 gene mutations.

Ross OA, Toft M, Haugarvoll K.

Neurology. 2008 Jul 22;71(4):303; author reply 303-4. doi: 10.1212/01.wnl.0000320511.30222.dd. No abstract available.

PMID:
18645174
3.

The LRRK2 G2019S mutation in Ashkenazi Jews with Parkinson disease: is there a gender effect?

Orr-Urtreger A, Shifrin C, Rozovski U, Rosner S, Bercovich D, Gurevich T, Yagev-More H, Bar-Shira A, Giladi N.

Neurology. 2007 Oct 16;69(16):1595-602.

PMID:
17938369
4.

Screening for the LRRK2 G2019S and codon-1441 mutations in a pathological series of parkinsonian syndromes and frontotemporal lobar degeneration.

Gaig C, Ezquerra M, Martí MJ, Valldeoriola F, Muñoz E, Lladó A, Rey MJ, Cardozo A, Molinuevo JL, Tolosa E.

J Neurol Sci. 2008 Jul 15;270(1-2):94-8. doi: 10.1016/j.jns.2008.02.010.

PMID:
18353371
5.

Frequency of LRRK2 mutations in early- and late-onset Parkinson disease.

Clark LN, Wang Y, Karlins E, Saito L, Mejia-Santana H, Harris J, Louis ED, Cote LJ, Andrews H, Fahn S, Waters C, Ford B, Frucht S, Ottman R, Marder K.

Neurology. 2006 Nov 28;67(10):1786-91.

PMID:
17050822
6.

Genetic analysis of LRRK2 P755L variant in Caucasian patients with Parkinson's disease.

Deng H, Le W, Huang M, Xie W, Pan T, Jankovic J.

Neurosci Lett. 2007 May 29;419(2):104-7.

PMID:
17482357
7.

A study of LRRK2 mutations and Parkinson's disease in Brazil.

Pimentel MM, Moura KC, Abdalla CB, Pereira JS, de Rosso AL, Nicaretta DH, Campos M Jr, de Almeida RM, dos Santos JM, Bastos IC, Mendes MF, Maultasch H, Costa FH, Werneck AL, Santos-Rebouças CB.

Neurosci Lett. 2008 Mar 5;433(1):17-21. doi: 10.1016/j.neulet.2007.12.033.

PMID:
18201824
8.

LRRK2 gene in Parkinson disease: mutation analysis and case control association study.

Paisán-Ruíz C, Lang AE, Kawarai T, Sato C, Salehi-Rad S, Fisman GK, Al-Khairallah T, St George-Hyslop P, Singleton A, Rogaeva E.

Neurology. 2005 Sep 13;65(5):696-700.

PMID:
16157901
9.

LRRK2 mutations in Spanish patients with Parkinson disease: frequency, clinical features, and incomplete penetrance.

Gaig C, Ezquerra M, Marti MJ, Muñoz E, Valldeoriola F, Tolosa E.

Arch Neurol. 2006 Mar;63(3):377-82.

PMID:
16533964
10.

LRRK2 is not a significant cause of Parkinson's disease in French-Canadians.

Dupré N, Rivière JB, Myers RH, Provencher P, Pourcher E, Emond F, Rouleau GA.

Can J Neurol Sci. 2007 Aug;34(3):333-5.

PMID:
17803032
11.

Analysis of 14 LRRK2 mutations in Parkinson's plus syndromes and late-onset Parkinson's disease.

Tan EK, Skipper L, Chua E, Wong MC, Pavanni R, Bonnard C, Kolatkar P, Liu JJ.

Mov Disord. 2006 Jul;21(7):997-1001.

PMID:
16602113
12.

LRRK2 exon 41 mutations in sporadic Parkinson disease in Europeans.

Lesage S, Janin S, Lohmann E, Leutenegger AL, Leclere L, Viallet F, Pollak P, Durif F, Thobois S, Layet V, Vidailhet M, Agid Y, Dürr A, Brice A; French Parkinson's Disease Genetics Study Group., Bonnet AM, Borg M, Broussolle E, Damier P, Destée A, Martinez M, Penet C, Rasco O, Tison F, Tranchan C, Vérin M.

Arch Neurol. 2007 Mar;64(3):425-30.

PMID:
17353388
13.

Is the G2019S LRRK2 mutation common in all southern European populations?

Papapetropoulos S, Adi N, Shehadeh L, Bishopric N, Singer C, Argyriou AA, Chroni E.

J Clin Neurosci. 2008 Sep;15(9):1027-30. doi: 10.1016/j.jocn.2007.08.013.

PMID:
18617409
14.

Comprehensive screening of a North American Parkinson's disease cohort for LRRK2 mutation.

Johnson J, Paisán-Ruíz C, Lopez G, Crews C, Britton A, Malkani R, Evans EW, McInerney-Leo A, Jain S, Nussbaum RL, Foote KD, Mandel RJ, Crawley A, Reimsnider S, Fernandez HH, Okun MS, Gwinn-Hardy K, Singleton AB.

Neurodegener Dis. 2007;4(5):386-91.

PMID:
17622782
15.

A clinic-based study of the LRRK2 gene in Parkinson disease yields new mutations.

Zabetian CP, Samii A, Mosley AD, Roberts JW, Leis BC, Yearout D, Raskind WH, Griffith A.

Neurology. 2005 Sep 13;65(5):741-4.

PMID:
16157909
16.

LRRK2 and Parkinson's disease in Norway.

Toft M, Haugarvoll K, Ross OA, Farrer MJ, Aasly JO.

Acta Neurol Scand Suppl. 2007;187:72-5.

PMID:
17419834
17.

LRRK2 and Parkin mutations in a family with parkinsonism-Lack of genotype-phenotype correlation.

Marras C, Klein C, Lang AE, Wakutani Y, Moreno D, Sato C, Yip E, Munhoz RP, Lohmann K, Djarmati A, Bi A, Rogaeva E.

Neurobiol Aging. 2010 Apr;31(4):721-2. doi: 10.1016/j.neurobiolaging.2008.05.030.

PMID:
18644660
18.

A common leucine-rich repeat kinase 2 gene mutation in familial and sporadic Parkinson's disease in Russia.

Illarioshkin SN, Shadrina MI, Slominsky PA, Bespalova EV, Zagorovskaya TB, Bagyeva GKh, Markova ED, Limborska SA, Ivanova-Smolenskaya IA.

Eur J Neurol. 2007 Apr;14(4):413-7.

PMID:
17388990
19.

The G2019S LRRK2 mutation is rare in Korean patients with Parkinson's disease.

Cho JW, Kim SY, Park SS, Kim HJ, Ahn TB, Kim JM, Jeon BS.

Can J Neurol Sci. 2007 Feb;34(1):53-5.

PMID:
17352347
20.

Clinical heterogeneity of the LRRK2 G2019S mutation.

Papapetropoulos S, Singer C, Ross OA, Toft M, Johnson JL, Farrer MJ, Mash DC.

Arch Neurol. 2006 Sep;63(9):1242-6.

PMID:
16966501
Items per page

Supplemental Content

Support Center